Primary prophylaxis of gastroesophageal variceal bleeding: Consensus recommendations of the Asian Pacific Association for the Study of the Liver

Hepatology International

Volumn 2, Issue 4, 2008, Pages 429-439

  Sarin, Shiv Kumar ^a   Kumar, Ashish ^a   Angus, Peter W ^a   Baijal, Sanjay Saran ^a   Chawla, Yogesh Kumar ^a   Dhiman, Radha Krishna ^a   Janaka de Silva, H ^a   Hamid, Saeed ^a   Hirota, Shozo ^a   Hou, Ming Chih ^a   Jafri, Wasim ^a   Khan, Mobin ^a   Lesmana, Laurentius A ^a   Lui, Hock F ^a   Malhotra, Veena ^a   Maruyama, Hitoshi ^a   Mazumder, Debendranath Guha ^a   Omata, Masao ^a   Poddar, Ujjal ^a   Puri, Amrinder S ^a   Sharma, Praveen ^a   Qureshi, Huma ^a   Raza, Rizvi Moattar ^a   Sahni, Peush ^a   Sakhuja, Puja ^a   Salih, Mohammad ^a   Santra, Amal ^a   Sharma, Barjesh Chander ^a   Shah, Hasnain Ali ^a   Shiha, Gamal ^a   Sollano, Jose ^a   more..

^a UNIVERSITY OF DELHI   (India)

Author keywords

Cirrhosis; GI bleed; Guidelines; Varices

Indexed keywords

ACETYLSALICYLIC ACID; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; ENBUCRILATE; ISOSORBIDE 5 NITRATE; NADOLOL; NONSTEROID ANTIINFLAMMATORY AGENT; OCTREOTIDE; PLACEBO; PROPRANOLOL; PROTON PUMP INHIBITOR; SUCRALFATE; TIMOLOL;

ALCOHOL CONSUMPTION; ASIA; CAPSULE ENDOSCOPY; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; DRUG EFFICACY; DRUG SAFETY; DRUG WITHDRAWAL; ENDOSCOPIC SCLEROTHERAPY; ESOPHAGUS ULCER; ESOPHAGUS VARICES; ESOPHAGUS VARICES BLEEDING; GASTROINTESTINAL ENDOSCOPY; HEMODYNAMICS; HUMAN; HYPEREMIA; INJECTION SITE BLEEDING; LIVER CIRRHOSIS; MONOTHERAPY; MORTALITY; PARACENTESIS; PORTAL HYPERTENSION; PRIMARY PREVENTION; PRIORITY JOURNAL; REVIEW; RISK REDUCTION; STOMACH HEMORRHAGE; STOMACH VARICES; UNSPECIFIED SIDE EFFECT;

EID: 57149113717     PISSN: 19360533     EISSN: 19360541     Source Type: Journal    
DOI: 10.1007/s12072-008-9096-8     Document Type: Review

References (106)

1. de Franchis R. Evolving Consensus in Portal Hypertension Report of the Baveno IV Consensus Workshop on methodology of diagnosis and therapy in portal hypertension. J Hepatol 2005;43:167-176
2. Garcia-Tsao G, Sanyal AJ, Grace ND, Carey W. Practice Guidelines Committee of the American Association for the Study of Liver Diseases. Practice Parameters Committee of the American College of Gastroenterology. Prevention and management of gastroesophageal varices and variceal hemorrhage in cirrhosis. Hepatology 2007;46(3):922-938. doi: 10.1002/hep.21907
3. Grace ND. Diagnosis and treatment of gastrointestinal bleeding secondary to portal hypertension. Am J Gastroenterol 1997;92:1081-1091
4. Centre for evidence-based medicine. Levels of evidence. 2001. http://www.cebm.net/index.aspx?o=1047. Accessed 23 Aug 2008
5. de Franchis R, Pascal JP, Burroughs AK, Henderson JM, Fleig W, Groszmann RJ, et al. Definitions, methodology and therapeutic strategies in portal hypertension. A consensus development workshop. J Hepatol 1992;15:256-261. doi: 10.1016/0168-8278(92)90044-P
6. Grace ND, Groszmann RJ, Garcia-Tsao G, Burroughs AK, Pagliaro L, Makuch RW, et al. Portal hypertension and variceal bleeding: An AASLD single topic symposium. Hepatology 1998;28:868-880. doi: 10.1002/hep.510280339
7. D'Amico G, Garcia-Tsao G, Cales P, Escorsell A, Nevens F, Cestari R, et al. Diagnosis of portal hypertension: How and when. In de Franchis R, editor. Portal Hypertension III. Proceedings of the Third Baveno International Consensus Workshop on Definitions, Methodology and Therapeutic Strategies. Oxford, UK: Blackwell Science; 2001. 36-64
8. The North Italian Endoscopic Club for the Study and Treatment of Esophageal Varices. Prediction of the first variceal hemorrhage in patients with cirrhosis of the liver and esophageal varices. A prospective multicenter study. N Engl J Med 1988;319:983-989
9. El-Serag HB, Everhart JE. Improved survival after variceal hemorrhage over an 11-year period in the Department of Veterans Affairs. Am J Gastroenterol 2000;95:3566-3573. doi: 10.1111/j.1572-0241.2000.03376.x
10. D'Amico G, de Franchis R. Upper digestive bleeding in cirrhosis. Posttherapeutic outcome and prognostic indicators. Hepatology 2003;38:599-612. doi: 10.1053/jhep.2003.50385
11. Carbonell N, Pauwels A, Serfaty L, Fourdan O, Levy VG, Poupon R. Improved survival after variceal bleeding in patients with cirrhosis over the past two decades. Hepatology 2004;40:652-659. doi: 10.1002/ hep.20339
12. Moitinho E, Escorsell A, Bandi JC, Salmeron JM, Garcia-Pagan JC, Rodes J, et al. Prognostic value of early measurements of portal pressure in acute variceal bleeding. Gastroenterology 1999;117:626-631. doi: 10.1016/ S0016-5085(99)70455-5
13. Groszmann RJ, Garcia-Tsao G, Bosch J, Grace ND, Burroughs AK, Planas R, et al. Portal Hypertension Collaborative Group. Betablockers to prevent gastroesophageal varices in patients with cirrhosis. N Engl J Med 2005;353:2254-2261. doi: 10.1056/NEJMoa044456
14. D'Amico G, Morabito A. Noninvasive markers of esophageal varices: another round, not the last. Hepatology 2004;39:30-34. doi: 10.1002/ hep.20018
15. Eisen GM, Eliakim R, Zaman A, Schwartz J, Faigel D, Rondonotti E, et al. The accuracy of PillCam ESO capsule endoscopy versus conventional upper endoscopy for the diagnosis of esophageal varices: A prospective three-center pilot study. Endoscopy 2006;38:31-35. doi: 10.1055/ s-2005-921189
16. Lapalus MG, Dumortier J, Fumex F, Roman S, Lot M, Prost B, et al. Esophageal capsule endoscopy versus esophagogastroduodenoscopy for evaluating portal hypertension: A prospective comparative study of performance and tolerance. Endoscopy 2006;38:36-41. doi: 10.1055/ s-2006-924975
17. Reliability of endoscopy in the assessment of variceal features: The Italian Liver Cirrhosis Project. J Hepatol 1987;4:93-98. doi: 10.1016/ S0168-8278(87)80015-6
18. Sarin S, Lamba GS, Kumar M, Misra A, Murthy NS. Comparison of endoscopic ligation and propranolol for the primary prevention of variceal bleeding. N Engl J Med 1999;340:988-993. doi: 10.1056/NEJM199904013401302
19. Merli M, Nicolini G, Angeloni S, Rinaldi V, De Santis A, Merkel C, et al. Incidence and natural history of small esophageal varices in cirrhotic patients. J Hepatol 2003;38:266-272. doi: 10.1016/ S0168-8278(02)00420-8
20. Conn HO, Grace ND, Bosch J, Groszmann J, Rodes J, Wright SC, et al. Propranolol in the prevention of the first hemorrhage from esophagogastric varices: A multicenter, randomized clinical trial. Hepatology 1991;13:902-912
21. The PROVA Study Group. Prophylaxis of first hemorrhage from esophageal varices by sclerotherapy, propranolol or both in cirrhotic patients. A randomized multicenter trial. Hepatology 1991;14:1016-1024
22. Angelico M, Carli L, Piat C, Gentile S, Capocaccia L. Effects of isosorbide-5-mononitrate compared with propranolol on first bleeding and long-term survival in cirrhosis. Gastroenterology 1997;113:1632-1639. doi: 10.1053/gast.1997.v113.pm9352866
23. Garcia-Pagan JC, Villanueva C, Vila MC, Albillos A, Genesca J, Ruiz del Arbol L, et al. Mononitrato Varices Esofagicas: Isosorbide mononitrate in the prevention of first variceal bleed in patients who cannot receive beta-blockers. Gastroenterology 2001;121:908-914. doi: 10.1053/ gast.2001.27993
24. Merkel C, Marin R, Sacerdoti D, Donada C, Cavallarin G, Torboli P, et al. Long-term results of a clinical trial of nadolol with or without isosorbide mononitrate for primary prophylaxis of variceal bleeding in cirrhosis. Hepatology 2000;31:324-329. doi: 10.1002/hep.510310210
25. Cales P, Oberti F, Payen JL, Naveau S, Guyader D, Blanc P, et al. Lack of effect of propranolol in the prevention of large oesophageal varices in patients with cirrhosis: A randomized trial. French-speaking Club for the study of portal hypertension. Eur J Gastroenterol Hepatol 1999;11:741-745. doi: 10.1097/00042737-199907000-00011
26. Merkel C, Marin R, Angeli P, Zanella P, Felder M, Bernardinello E, et al. A placebo-controlled clinical trial of nadolol in the prophylaxis of growth of small esophageal varices in cirrhosis. Gastroenterology 2004;127:476-484. doi: 10.1053/j.gastro.2004.05.004 476-484.
27. Staritz M, Poralla T, Meyer zum Büschenfelde KH. Intravascular oesophageal variceal pressure (IOVP) assessed by endoscopic fine needle puncture under basal conditions, Valsalva's manoeuvre and after glyceryltrinitrate application. Gut 1985;26(5):525-530. doi: 10.1136/ gut.26.5.525
28. Kravetz D, Romero G, Argonz J, Guevara M, Suarez A, Abecasis R, et al. Total volume paracentesis decreases variceal pressure, size, and variceal wall tension in cirrhotic patients. Hepatology 1997;25(1):59-62. doi: 10.1002/hep.510250111
29. Luca A, Feu F, García-Pagán JC, Jiménez W, Arroyo V, Bosch J, et al. Favorable effects of total paracentesis on splanchnic hemodynamics in cirrhotic patients with tense ascites. Hepatology 1994;20(1 Pt 1):30-33
30. Escorsell A, Ginès A, Llach J, García-Pagán JC, Bordas JM, Bosch J, et al. Increasing intra-abdominal pressure increases pressure, volume, and wall tension in esophageal varices. Hepatology 2002;36(4 Pt 1):936-940
31. Luca A, Cirera I, García-Pagán JC, Feu F, Pizcueta P, Bosch J, et al. Hemodynamic effects of acute changes in intra-abdominal pressure in patients with cirrhosis. Gastroenterology 1993;104(1):222-227
32. García-Pagàn JC, Santos C, Barberá JA, Luca A, Roca J, Rodriguez-Roisin R, et al. Physical exercise increases portal pressure in patients with cirrhosis and portal hypertension. Gastroenterology 1996;111(5):1300-1306. doi: 10.1053/ gast.1996.v111.pm8898644
33. Bandi JC, García-Pagán JC, Escorsell A, François E, Moitinho E, Rodés J, et al. Effects of propranolol on the hepatic hemodynamic response to physical exercise in patients with cirrhosis. Hepatology 1998;28(3):677-682. doi: 10.1002/hep.510280312
34. Feu F, Bordas JM, Luca A, García-Pagán JC, Escorsell A, Bosch J, et al. Reduction of variceal pressure by propranolol: comparison of the effects on portal pressure and azygos blood flow in patients with cirrhosis. Hepatology 1993;18(5):1082-1089
35. Luca A, García-Pagán JC, Bosch J, Feu F, Caballeráa J, Groszmann RJ, et al. Effects of ethanol consumption on hepatic hemodynamics in patients with alcoholic cirrhosis. Gastroenterology 1997;112(4):1284-1289. doi: 10.1016/S0016-5085(97)70142-2
36. Ready JB, Hossack KF, Rector WG Jr. The effects of ethanol administration on portal pressure and gastroesophageal collateral blood flow in patients with alcoholic cirrhosis. Hepatology 1990;11(4):674-677. doi: 10.1002/hep.1840110422
37. Albillos A, Bañares R, González M, Catalina MV, Pastor O, Gonzalez R, et al. The extent of the collateral circulation influences the postprandial increase in portal pressure in patients with cirrhosis. Gut 2007;56(2):259-264. doi: 10.1136/gut.2006.095240
38. Albillos A, Rossi I, Iborra J, Lledó JL, Calleja JL, Barrios C, et al. Octreotide prevents postprandial splanchnic hyperemia in patients with portal hypertension. J Hepatol 1994;21(1):88-94. doi: 10.1016/ S0168-8278(94)80142-8
39. Ludwig D, Schädel S, Brúning A, Schiefer B, Stange EF. 48-hour hemodynamic effects of octreotide on postprandial splanchnic hyperemia in patients with liver cirrhosis and portal hypertension: double-blind, placebo-controlled study. Dig Dis Sci 2000;45(5):1019-1027. doi: 10.1023/A:1005553914878
40. Buonamico P, Sabbá C, Garcia-Tsao G, Berardi E, Antonica G, Ferraioli G, et al. Octreotide blunts postprandial splanchnic hyperemia in cirrhotic patients: A double-blind randomized echo-Doppler study. Hepatology 1995;21(1):134-139
41. de Lédinghen V, Mannant PR, Foucher J, Perault MC, Barrioz T, Ingrand P, et al. Non-steroidal anti-inflammatory drugs and variceal bleeding: A case-control study. J Hepatol 1996;24(5):570-573. doi: 10.1016/S0168-8278(96)80142-5
42. de Lédinghen V, Heresbach D, Fourdan O, Bernard P, Liebaert-Bories MP, Nousbaum JB, et al. Anti-inflammatory drugs and variceal bleeding: A case-control study. Gut 1999;44(2):270-273
43. Colle I, De Vriese AS, Van Vlierberghe H, Lameire NH, DeVos M. Systemic and splanchnic haemodynamic effects of sildenafil in an in vivo animal model of cirrhosis support for a risk in cirrhotic patients. Liver Int 2004;24(1):63-68. doi: 10.1111/j.1478-3231.2004.00892.x
44. Poynard T, Cales P, Pasta L, Ideo G, Pascal JP, Pagliaro L, et al. Betaadrenergic-antagonist drugs in the prevention of gastrointestinal bleeding in patients with cirrhosis and esophageal varices. An analysis of data and prognostic factors in 589 patients from four randomized clinical trials, Franco-Italian Multicenter Study Group. N Engl J Med 1991;324:1532-1538
45. Pagliaro L, D'Amico G, Sorensen TI, Lebrec D, Burroughs AK, Morabito A, et al. Prevention of first bleeding in cirrhosis. A meta-analysis of randomized trials of nonsurgical treatment. Ann Intern Med 1992;117:59-70
46. D'Amico G, Pagliaro L, Bosch J. Pharmacological treatment of portal hypertension: An evidence-based approach. Semin Liver Dis 1999;19:475-505
47. Merkel C, Bolognesi M, Sacerdoti D, et al. The hemodynamic response to medical treatment of portal hypertension as a predictor of clinical effectiveness in the primary prophylaxis of variceal bleeding in cirrhosis. Hepatology 2000;32:930-934. doi: 10.1053/jhep.2000.19322
48. Bosch J. A la carte or menu fixed: Improving pharmacologic therapy of portal hypertension. Hepatology 2002;36:1330-1332
49. Feu F, Garcia-Pagan JC, Bosch J, Luca A, Teres J, Escorsell A, et al. Relation between portal pressure response to pharmacotherapy and risk of recurrent variceal haemorrhage in patients with cirrhosis. Lancet 1995;346:1056-1059. doi: 10.1016/S0140-6736(95)91740-3
50. Villanueva C, Balanzo J, Novella MT, Soriano G, Sainz S, Torras X, et al. Nadolol plus isosorbide mononitrate compared with sclerotherapy for the prevention of variceal rebleeding. N Engl J Med 1996;334:1624-1629. doi: 10.1056/NEJM199606203342502
51. Bureau C, Peron JM, Alric L, Morales J, Sanchez J, Barange K, et al. "A la carte" treatment of portal hypertension: Adapting medical therapy to hemodynamic response for the prevention of bleeding. Hepatology 2002;36:1361-1366
52. Aracil C, Lopez-Balaguer JM, Monfort D, Piqueras M, Gonzalez B, Minana J, et al. Hemodynamic response to beta-blockers and prediction of clinical efficacy in the primary prophylaxis of variceal bleeding in patients with cirrhosis. Hepatology 2003;38:296A. abstract doi: 10.1016/ S0270-9139(03)80334-8
53. Sarin SK, Guptan RC, Jain AK, Sundaram KR. A randomized controlled trial of endoscopic variceal band ligation for primary prophylaxis of variceal bleeding. Eur J Gastroenterol Hepatol 1996;8:337-342. doi: 10.1097/ 00042737-199604000-00010
54. Lo GH, Chen WC, Chen MH, Lin CP, Lo CC, Hsu PI, et al. Endoscopic ligation vs. nadolol in the prevention of first variceal bleeding in patients with cirrhosis. Gastrointest Endosc 2004;59:333-338. doi: 10.1016/S0016-5107(03)02819-0
55. Schepke M, Kleber G, Nurnberg D, Willert J, Koch L, Veltzke-Schlieker W, et al. Ligation versus propranolol for the primary prophylaxis of variceal bleeding in cirrhosis. Hepatology 2004;40:65-72. doi: 10.1002/ hep.20284
56. Lay CS, Tsai YT, Lee FY, Lai YL, Yu CJ, Chen CB, et al. Endoscopic variceal ligation versus propranolol in prophylaxis of first variceal bleeding in patients with cirrhosis. J Gastroenterol Hepatol 2006;21:413-419. doi: 10.1111/j.1440-1746.2005.04071.x
57. Jutabha R, Jensen DM, Martin P, Savides T, Han SH, Gornbein J. Randomized study comparing banding and propranolol to prevent initial variceal hemorrhage in cirrhotics with high-risk esophageal varices. Gastroenterology 2005;128:870-881. doi: 10.1053/j.gastro.2005.01.047
58. Imperiale TF, Chalasani N. A meta-analysis of endoscopic variceal ligation for primary prophylaxis of oesophageal variceal bleeding. Hepatology 2001;33:802-807. doi: 10.1053/jhep.2001.23054
59. Teran JC, Imperiale TF, Mullen KD, Tavill AS, McCullough AJ. Primary prophylaxis of variceal bleeding in cirrhosis: A cost-effectiveness analysis. Gastroenterology 1997;112:473-482. doi: 10.1053/ gast.1997.v112.pm9024301
60. Shaheen NJ, Stuart E, Scmidt SM, Mitchell K, Fried M, et al. Pantoprazole reduces the size of post banding ulcers after variceal band ligation: A randomized controlled trial. Hepatology 2005;41:588-594. doi: 10.1002/hep.20593
61. Yoshida H, Mamada Y, Taniai N, Yamamoto K, Kawano Y, Mizuguchi Y, et al. A randomized control trial of bi-monthly versus bi-weekly endoscopic variceal ligation of oesophageal varices. Am J Gastroenterol 2005;100(9):2005-2009. doi: 10.1111/j.1572-0241.2005.41864.x
62. De Franchis R. Endoscopy critics vs endoscopy enthusiasts for primary prophylaxis of variceal bleeding. Hepatology 2006;43:24-26. doi: 10.1002/ hep.21026
63. Chen CY, Sheu MZ, Su SY. Prophylactic endoscopic variceal ligation (EVL) with multiple band ligator for esophageal varices. Gastroenterology 1998;114(Suppl):A1224. abstract
64. De BK, Ghoshal UK, Das T, Santra A, Biswas PK. Endoscopic variceal ligation for primary prophylaxis of oesophageal variceal bleed: preliminary report of a randomized controlled trial. J Gastroenterol Hepatol 1999;14:220-224. doi: 10.1046/j.1440-1746.1999.01800.x
65. Lui HF, Stanley AJ, Forrest EH, Jalan R, Hislop WS, Mills PR, et al. Primary prophylaxis of variceal haemorrhage: A randomized controlled trial comparing band ligation, propranolol, and isosorbide mononitrate. Gastroenterology 2002;123:735-744. doi: 10.1053/gast.2002.35385
66. Thuluvath PJ, Maheshwari A, Jagannath S, Arepally A. A randomized controlled trial of β-blockers versus endoscopic band ligation for primary prophylaxis: A large sample size is required to show a difference in bleeding rates. Dig Dis Sci 2005;50:407-410. doi: 10.1007/ s10620-005-1619-8
67. Psilopoulos D, Galanis P, Goulas S, Papanikolaou IS, Elefsiniotis I, Liatsos C, et al. Endoscopic variceal ligation vs. propranolol for prevention of first variceal bleeding: A randomized controlled trial. Eur J Gastroenterol Hepatol 2005;17(10):1111-1117. doi: 10.1097/ 00042737-200510000-00016
68. Khuroo MS, Khuroo NS, Farahat KLC, Khuroo YS, Sofi AA, Dahab ST. Meta-analysis: Endoscopic variceal ligation for primary prophylaxis of oesophageal variceal bleeding. Aliment Pharmacol Ther 2005;21:347-361. doi: 10.1111/j.1365-2036.2005.02346.x
69. Sarin SK, Wadhawan M, Agarwal SR, Tyagi P, Sharma BC. Endoscopic variceal ligation plus propranolol versus endoscopic variceal ligation alone in primary prophylaxis of variceal bleeding. Am J Gastroenterol 2005;100:797-804. doi: 10.1111/j.1572-0241.2005.40468.x
70. Angelico M, Carli L, Piat C, Gentile S, Rinaldi V, Bologna E, et al. Isosorbide-5-mononitrate versus propranolol in the prevention of first bleeding in cirrhosis. Gastroenterology 1993;104:1460-1465
71. Groszmann RJ. Beta-adrenergic blockers and nitrovasodilators for the treatment of portal hypertension: The good, the bad, the ugly. Gastroenterology 1998;113:1794-1797. doi: 10.1053/ gast.1997.v113.agast971131794
72. Borroni G, Salerno F, Cazzaniga M, Bissoli F, Lorenzano E, Maggi A, et al. Nadolol is superior to isosorbide mononitrate for the prevention of the first variceal bleeding in cirrhotic patients with ascites. J Hepatol 2002;37:315-321. doi: 10.1016/S0168-8278(02)00174-5
73. Merkel C, Marin R, Enzo E, Donada C, Cavallarin G, Torboli P, et al. Randomised trial of nadolol alone or with isosorbide mononitrate for primary prophylaxis of variceal bleeding in cirrhosis. Lancet 1996;348:1677-1681. doi: 10.1016/S0140-6736(96)05406-2
74. Garcia-Pagan JC, Morillas R, Banares R, Albillos A, Villanueva C, Vila C, et al. Propranolol plus placebo versus propranolol plus isosorbide-5-mononitrate in the prevention of a first variceal bleed: A double-blind RCT. Hepatology 2003;37:1260-1266. doi: 10.1053/ jhep.2003.50211
75. D'Amico G, Pasta L, Politi F, Vizzini G, Traina M, Caltagirone M, et al. Isosorbide mononitrate with nadolol compared to nadolol alone for prevention of the first bleeding in cirrhosis. A double-blind placebo-controlled randomized trial. Gastroenterol Int 2002;15:40-50
76. Sarin SK, Lahoti D, Saxena SP, Murthy NS, Makwana UK. Prevalence, classification and natural history of gastric varices: A long-term follow-up study in 568 portal hypertension patients. Hepatology 1992;16:1343-1349. doi: 10.1002/hep.1840160607
77. Sarin SK, Primignani M, Agarwal SR. Gastric varices. In: De Franchis R, editor. Proceedings of the third Baveno international consensus workshop on definitions, methodology and therapeutic strategies. Oxford: Blackwell Science; 2001. p. 76-96
78. Hosking SW, Johnson AG. Gastric varices: A proposed classification leading to management. Br J Surg 1988;75:195-196. doi: 10.1002/ bjs.1800750303
79. Kim T, Shijo H, Kokawa H, Tokumitsu H, Kubara K, Ota K, et al. Risk factors for hemorrhage from gastric fundal varices. Hepatology 1997;25:307-312. doi: 10.1002/hep.510250209
80. Hashizume M, Kitano S, Yamaga H, Koyanagi N, Sugimachi K. Endoscopic classification of gastric varices. Gastrointest Endosc 1990;36:276-280
81. Arakawa M, Masuzaki T, Okuda K. Pathology of fundic varices of the stomach and rupture. J Gastroenterol Hepatol 2002;17:1064-1069. doi: 10.1046/j.1440-1746.2002.02855.x
82. D'Amico G, Pagliaro L, Bosch J. The treatment of portal hypertension: A meta-analytic review. Hepatology 1995;22:332-354
83. Ramond MJ, Valla D, Mosnier JF, Degott C, Bernuau J, Rueff B, et al. Successful endoscopic obturation of gastric varices with butyl cyanoacrylate. Hepatology 1989;10:488-493. doi: 10.1002/hep.1840100415
84. Oho K, Iwao T, Sumino M, Toyonaga A, Tanikawa K. Ethanolamine oleate versus butyl cyanoacrylate for bleeding gastric varices: A nonrandomized study. Endoscopy 1995;27:349-354
85. Sarin SK, Jain AK, Jain M, Gupta R. A randomized controlled trial of cyanoacrylate versus alcohol injection in patients with isolated fundic varices. Am J Gastroenterol 2002;97:1010-1015. doi: 10.1111/ j.1572-0241.2002.05622.x
86. Rengstorff DS, Binmoeller KF. A pilot study of 2-octyl-cyanoacrylate injection for treatment of gastric fundal varices in humans. Gastrointest Endosc 2004;59:553-558. doi: 10.1016/S0016-5107(03)02865-7
87. Roesch W, Rexroth G. Pulmonary, cerebral and coronary emboli during bucrylate injection of bleeding fundic varices. Endoscopy 1998;30:S89-S90
88. See A, Florent C, Lamy P, Levy VG, Bouvry M. Cerebrovascular accidents after endoscopic obturation of oesophageal varices with isobutyl-2-cyanoacrylate in 2 patients. Gastroenterol Clin Biol 1986;10:604-607
89. Kanagawa H, Mima H, Kouyama H, Gotoh K, Uchida T, Okuda K. Treatment of gastric fundal varices by balloon-occluded retrograde transvenous obliteration. J Gastroenterol Hepatol 1996;11:51-58. doi: 10.1111/ j.1440-1746.1996.tb00010.x
90. Hamamoto N, Matsumoto A, Nomura T, Kayazawa M, Hirata I, Morikawa H, et al. Treatment of gastric fundal varices by balloon endoscopic sclerotherapy. Gastrointest Endosc 1999;49:115-118. doi: 10.1016/ S0016-5107(99)70459-1
91. Shiba M, Higuchi K, Nakamura K, Itani A, Kuga T, Okazaki H, et al. Efficacy and safety of balloon-occluded endoscopic injection for sclerotherapy as a prophylactic treatment for high-risk gastric varices: a prospective, randomized, comparative clinical trial. Gastrointest Endosc 2002;56:522-528. doi: 10.1016/S0016-5107(02)70437-9
92. Matsumoto A, Hamamoto N, Kayazawa M. Balloon endoscopic sclerotherapy, a novel treatment for high-risk gastric fundal varices: A pilot study. Gastroenterology 1999;117:515-516. doi: 10.1053/gast.1999.0029900515
93. Fukuda T, Hirota S, Sugimura K. Long-term results of balloon occluded retrograde transvenous obliteration for the treatment of gastric varices and hepatic encephalopathy. J Vasc Interv Radiol 2001;12:327-336. doi: 10.1016/S1051-0443(07)61912-5
94. Cho SK, Shin SW, Lee IH, Do YS, Choo SW, Park KB, et al. Balloon-occluded retrograde transvenous obliteration of gastric varices: outcomes and complications in 49 patients. AJR Am J Roentgenol 2007;189(6):W365-W372. doi: 10.2214/AJR.07.2266
95. Arai H, Abe T, Takagi H, Mori M. Efficacy of balloon-occluded retrograde transvenous obliteration, percutaneous transhepatic obliteration and combined techniques for the management of gastric fundal varices. World J Gastroenterol 2006;12(24):3866-3873
96. Mittal SK, Kalra KK, Aggarwal V. Diagnostic upper GI endoscopy for hematemesis in children: Experience from a pediatric gastroenterology centre in north India. Indian J Pediatr 1994;61:651-654. doi: 10.1007/ BF02751973
97. Yachha SK, Khanduri A, Sharma BC, Kumar M. Gastrointestinal bleeding in children. J Gastroenterol Hepatol 1996;11:903-907
98. Cox K, Ament ME. Upper gastrointestinal bleeding in children and adolescents. Pediatrics 1979;63:408-413
99. Dilawari JB, Chawla YK. Extrahepatic portal venous obstruction. Gut 1988;29:554-555. doi: 10.1136/gut.29.4.554
100. Bernard O, Alvarez F, Brunelle F, Hadchouel P, Alagille D. Portal hypertension in children. Clin Gastroenterol 1985;14:33-55
101. Howard ER, Stamatakis JD, Mowat AP. Management of esophageal varices in children by injection sclerotherapy. J Pediatr Surg 1984;19:2-5
102. Howard ER, Stringer MD, Mowat AP. Assessment of injection sclerotherapy in the management of 152 children with esophageal varices. Br J Surg 1988;75:404-408
103. Goncalves MEP, Cardoso SR, Maksoud JG. Prophylactic sclerotherapy in children with esophageal varices: Long-term results of a controlled prospective randomized trial. J Pediatr Surg 2000;35:401-405
104. Arora NK, Lodha R, Gulati S, et al. Portal hypertension in north Indian children. Indian J Pediatr 1998;65:585-591
105. Celinska-Cedro D, Teisseyre M, Woynarowski M, et al. Endoscopic ligation of esophageal varices for prophylaxis of first bleeding in children and adolescents with portal hypertension: Preliminary results of a prospective study. J Pediatr Surg 2003;38:1008-1011
106. Shashidhar H, Langhans N, Grand RJ. Propanolol in prevention of portal hypertensive hemorrhage in children: A pilot study. J Pediatr Gastroenterol Nutr 1999;29:12-17